Filtered By:
Condition: Atrial Fibrillation
Countries: Sweden Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 67 results found since Jan 2013.

Prevalence of atrial fibrillation and reasons for undertreatment with oral anticoagulants
ConclusionsIn the population of V ästernorrland County, a very high AF prevalence of 4.7% was found, of which just over 90% would theoretically benefit from OAC treatment. This is higher than previously reported and stresses the importance of stroke prevention in this large patient group.
Source: Journal of Thrombosis and Thrombolysis - September 13, 2023 Category: Hematology Source Type: research

The Connection Between Diabetes and Heart Arrhythmias
The human heart beats roughly 3 billion times during the course of an average lifetime. Every single time it beats, blood is drawn into its two upper chambers, held there briefly by a network of valves, and then pumped out forcefully through its two lower chambers. This drawing-and-pumping action ensures that about six liters of freshly oxygenated blood leaves the heart and enters the bloodstream every minute—a volume that can rise to more than 35 liters per minute when someone is exercising. [time-brightcove not-tgx=”true”] But none of that can happen unless the heart’s complicated machinery&md...
Source: TIME: Health - July 25, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate Source Type: news

Direct oral anticoagulants: patient reported adherence and minor bleedings
AbstractData regarding adherence and minor bleeding on direct oral anticoagulants in everyday life are still sparse. Inclusion criteria: treatment initiated with dabigatran, rivaroxaban or apixaban in non-valvular atrial fibrillation patients from a center in northern Sweden between 2011 and 2019 (n  = 668). Exclusion criteria: cognitive impairment, dose dispensing, need of interpreter or hospital admission (n = 67). By a telephone interview adherence was measured in 569 patients (response rate 94.8%) using the 8-item Morisky medication adherence scale and minor bleeding was asked for. CHA2DS2-VASc and HAS-BLED sco...
Source: Journal of Thrombosis and Thrombolysis - June 22, 2023 Category: Hematology Source Type: research

Waiting more than 24 hours for hip fracture surgery is associated with increased risk of adverse outcomes for sicker patients: a nationwide cohort study of 63,998 patients using the Swedish Hip Fracture Register
CONCLUSION: The associations between waiting > 24 hours for hip fracture surgery and AF, CHF, and acute ischemia suggest that shorter waiting time may reduce adverse outcomes for the sicker patients.PMID:36847752 | PMC:PMC9972166 | DOI:10.2340/17453674.2023.9595
Source: Acta Orthopaedica - February 27, 2023 Category: Orthopaedics Authors: Katarina Greve Stina Ek Erzs ébet Bartha Karin Modig Margareta Hedstr öm Source Type: research

Safety and effectiveness of rivaroxaban for prevention of stroke in patients with nonvalvular atrial fibrillation: analysis of routine clinical data from four countries
CONCLUSIONS: Incidences of intracranial bleeding were generally lower with rivaroxaban than with SOC, whereas incidences of gastrointestinal and urogenital bleeding were generally higher. The safety profile of rivaroxaban for NVAF in routine practice is consistent with findings from randomized controlled trials and other studies.PMID:36795067 | DOI:10.1080/14740338.2023.2181334
Source: Expert Opinion on Drug Safety - February 16, 2023 Category: Drugs & Pharmacology Authors: Luis Alberto Garc ía-Rodríguez Ana Ruig ómez Tania Schink Annemarie Voss Elisabeth Smits Karin M A Swart Yanina Balabanova Kiliana Suzart-Woischnik Gunnar Brobert Ron M C Herings Source Type: research

Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR  ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients ) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The me...
Source: Journal of Thrombosis and Thrombolysis - January 6, 2023 Category: Hematology Source Type: research

Bereavement in childhood and young adulthood and the risk of atrial fibrillation: a population-based cohort study from Denmark and Sweden
Adverse childhood life events are associated with increased risks of hypertension, ischemic heart disease, and stroke later in life. Limited evidence also suggests that stress in adulthood may increase the ris...
Source: BMC Medicine - January 5, 2023 Category: Internal Medicine Authors: Hua Chen, Imre Janszky, Mikael Rostila, Dang Wei, Fen Yang, Jiong Li and Krisztina D. L ászló Tags: Research article Source Type: research

Second death linked to potential antibody treatment for Alzheimer ’s disease
A 65-year-old woman who was receiving a promising experimental treatment to slow the cognitive decline caused by her early Alzheimer’s disease recently died from a massive brain hemorrhage that some researchers link to the drug. The clinical trial death, described in an unpublished case report Science has obtained, is the second thought to be associated with the antibody called lecanemab. The newly disclosed fatality intensifies questions about its safety and how widely lecanemab should be prescribed if ultimately approved by regulators. The woman, who received infusions of the antibody as part of the trial, s...
Source: ScienceNOW - November 28, 2022 Category: Science Source Type: news

Epidemiology of first and recurrent ischemic stroke in Sweden 2010 –2019 – A Riksstroke study
Conclusion: Whereas both first-ever and recurrent IS rates declined in Sweden between 2010 and 2019, the proportional decline was almost double for recurrent IS than for first-ever IS and most pronounced in the elderly. Increased use of secondary preventive drugs, in particular anticoagulants in atrial fibrillation, appears to have contributed, but further studies on precise causes for the decline in recurrent IS are needed.
Source: Neuroepidemiology - October 12, 2022 Category: Epidemiology Source Type: research

Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING): A Registry-Based Randomized Controlled Noninferiority Study
CONCLUSIONS: Early initiation was noninferior to delayed start of NOAC after acute ischemic stroke in patients with atrial fibrillation. Numerically lower rates of ischemic stroke and death and the absence of symptomatic intracerebral hemorrhages implied that the early start of NOAC was safe and should be considered for acute secondary stroke prevention in patients eligible for NOAC treatment.REGISTRATION: URL: http://www.CLINICALTRIALS: gov; Unique identifier: NCT02961348.PMID:36065821 | DOI:10.1161/CIRCULATIONAHA.122.060666
Source: Circulation - September 6, 2022 Category: Cardiology Authors: Jonas Oldgren Signild Åsberg Ziad Hijazi Per Wester Maria Bertilsson Bo Norrving National TIMING Collaborators Source Type: research

Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis
CONCLUSION: Adherence improving interventions for NVAF patients on DOACs such as chronic disease co-management and patient education can be cost-saving and cost-effective, within a range of costs that appear reasonable to the Swedish healthcare system.PMID:35997241 | DOI:10.1080/13696998.2022.2116848
Source: Journal of Medical Economics - August 23, 2022 Category: Health Management Authors: C Blomstr öm Lundqvist S Sj älander L A Garcia Rodriguez Ö Åkerborg G Jin A Caleyachetty M Huelsebeck K Bowrin B Schaefer H Mahdessian L Hofmeister L Å Levin Source Type: research